The human papilloma virus (HPV) is associated with the development of cervical cancer, genital warts and other cancers.  Although two HPV vaccines have been approved on the market: Gardasil in 2006, which protects against HPV-6 and HPV-11, and Cervarix in 2009, the vaccine applications are still limited to age barrier (WebMD, nd).  Gardasil is recommended as a routine vaccination for females aged 9-26 years old and for boys and men aged 11 to 21 while Cervarix, is recommended for use in females aged 10-25 years old. In the US, 20 million people are affected with HPV, and about 30 of the 100 HPV-types are transmitted sexually (Web MD, nd). Many epidemiological and experimental studies, indicated that 99% of cervical cancers contains HPV DNA, and four specific HPV types (6, 18, 31, and 45) cause at least 80% of diagnosed cervical cancers (Pagliusi, nd). World-wide, the prevalence of HPV infection ranges